Daniel Catenacci, MD


  • Section of Hematology/Oncology, Assistant Professor of Medicine


  • MD, Wayne State University 2003
  • BS, Univerisity of Waterloo, Waterloo, Canada 1999


The University of Chicago Medicine
Duchossois Center for Advanced Medicine
5758 S. Maryland Ave. 
Chicago, IL 60637


Phone: 773-702-7596


Dr. Catenacci's academic interests include laboratory investigation of cell signaling of normal cells and cancer cells, and the evaluation of novel molecular inhibitory targets based on these signaling pathways, with particular focus on receptor tyrosine kinases such as RON and MET tyrosine kinase. The ultimate goal of his research is to develop novel therapeutic agents to be used for the treatment of gastroesophageal and other malignancies. Other areas of academic interest include Phase I, II, and III clinical trials, drug development and the validation of molecular markers to be predictive and prognostic of patient outcomes. As such, he is actively involved as principle investigator for various gastrointestinal clinical trials, including the American Research and Recovery Act (ARRA) funded pancreatic cancer trial evaluating a novel Hedgehog pathway inhibitor combined with gemcitabine chemotherapy. Additionally, Dr. Catenacci is leading the translational laboratory research effort for these clinical trials for the Gastrointestinal Oncology program, in attempt to explain why some patients obtain benefit from novel therapies while others do not. Ultimately, he is interested in developing novel approaches to best provide personalized cutting edge cancer care for patients, based on the individual molecular characteristics of their cancer cells as well as their normal cells, while taking into account all aspects of the patient as a whole.

Research Papers on PubMed